ITGA2B and breast cancer: In addition, the reduced expression of GPIIb/IIIa observed on platelets after five weeks of breast cancer development may be associated with the increased fractions of platelet-tumor cell aggregates caused by the cross-linking observed between platelet integrins, primarily GPIIb/IIIa, and those expressed on tumor cells, such as αvβ3 [57, 58].